Where does ProMIS Neurosciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), ProMIS Neurosciences, Inc. ranks #32,950 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does ProMIS Neurosciences, Inc. hold?

ProMIS Neurosciences, Inc. holds 8 US utility patents granted between 2016 and 2025, spanning 7 technology areas.

What is ProMIS Neurosciences, Inc.'s Innovation Score?

ProMIS Neurosciences, Inc. has an Innovation Score of 33.4 out of 100 (44th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is ProMIS Neurosciences, Inc.'s patent grant rate increasing or decreasing?

ProMIS Neurosciences, Inc.'s recent grant velocity is -80% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for ProMIS Neurosciences, Inc.'s patents?

ProMIS Neurosciences, Inc.'s patents average 16.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the ProMIS Neurosciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

ProMIS Neurosciences, Inc.

Q: What technology areas does ProMIS Neurosciences, Inc. focus on?

ProMIS Neurosciences, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Promis ranks #32,950 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 7 technology areas.

#32,950
of 49,997 US assignees by volume: 44th percentile
by Innovation Score (33.4/100): 16.4
avg claims per patent: -80%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32950 · Foreign Corporation #32,950 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,950/49,997
PHOTO-FINISH Pristine Access
CPC-NARROW A61P · 7 areas
INNOV-THIN 33.4/100
CLAIMS-RICH 16.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -80% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Pristine Access Technologies Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Ayla Networks · near

33
Data Integrity… · near

33
Planmeca OY · near

33
ProMIS Neurosciences · this assignee

33
Therasyn Sensors · near

33
3D Lighting… · lowest

7

What this shows Promis's Innovation Score is 33.4/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Promis's grants concentrate

ProMIS Neurosciences, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2018. By volume, Promis sits between Pristine Access Technologies Ltd. and Proclara Biosciences, Inc..

Promis's three-year grant acceleration

ProMIS Neurosciences, Inc. shows 1 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Pristine Access

8
Pro Form Products

8
Pro-pure

8
Procom Heating

8
Proverum

8
Procella Therapeu…

8
Process Retail Gr…

8
Proclara Bioscien…

8
Promis Neuroscien… ◀

8

What this shows ProMIS holds 8 patents at rank #32,942, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near ProMIS

By rank, the assignees closest to #32,942 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in ProMIS's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for ProMIS, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (33 here).

Data Integrity Advisors, LLC 33 Therasyn Sensors, Inc. 33 Ayla Networks, Inc. 33 Planmeca OY 33

Promis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

ProMIS Neurosciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	25.0%
2017	2	25.0%
2018	1	12.5%
2024	1	12.5%
2025partial year	2	25.0%

Which technologies does ProMIS Neurosciences, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 8

C07K - Peptides 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C12Y - Enzymes 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

Top 7 of 7 technology areas

Where it ranks

Overall rank by patents

#32,950

of 49,997 tracked assignees

Innovation Score

33.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

ProMIS Neurosciences, Inc.'s patent record in context - here's where to go next.

ProMIS Neurosciences, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #32,950 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare ProMIS Neurosciences, Inc. against Pristine Access Technologies Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.